NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.510
0.00 (0.00%)
Jun 13, 2025, 4:00 PM - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,389,582
Market Cap
24.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NNVC News
- 10 days ago - NanoViricides Measles Drug Development Animal Study is Imminent - Accesswire
- 17 days ago - NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Accesswire
- 23 days ago - The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - Accesswire
- 4 weeks ago - Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution - Accesswire
- 5 weeks ago - NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC - Newsfile Corp
- 6 weeks ago - Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It - Accesswire
- 2 months ago - Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak - Accesswire
- 3 months ago - NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Accesswire